Protein and processes for producing the same

A novel protein and a process of producing the protein is provided. The protein is a glycoprotein having activity of suppressing the differentiation and/or maturation of adipocyte, having a molecular weight of about 45 kD under non-reducing conditions and about 28 kD and/or 23 kD under reducing conditions, and exhibiting affinity to heparin. A process of producing the protein comprising culturing human fibroblasts and purifying the culture broth by chromatography using an ion exchange column, affinity column, and reverse phase column. A cDNA encoding the protein and a process of producing the protein using the cDNA are also provided. The protein of the present invention is useful as a pharmaceutical composition for preventing or treating obesity or as an antigen for establishing immunological diagnosis, etc.

Novel protein and process for producing the same

ANTI-SIGLEC-15 ANTIBODY

Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.

Novel protein and process for producing the same

Proteins and methods for producing the proteins

A protein which inhibits osteoclast differentiation and/or maturation and a method for producing the protein. The protein is produced by human embryonic lung fibroblasts and has a molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis. The protein can be isolated and purified from the culture medium of fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity for the protein or a method for determining protein concentration using these antibodies.

ANTI-SIGLEC-15 ANTIBODY

Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like. 1. An antibody or antigen binding fragment thereof comprising: a light chain sequence that comprises a light chain variable region having CDRL1 , CDRL2 , and CDRL3 , wherein CDRL1 , comprises the amino acid sequence of SEQ ID NO: 47 , CDRL2 , comprises the amino acid sequence of SEQ ID NO: 48 , and CDRL3 , comprises the amino acid sequence of SEQ ID NO: 49 , and a heavy chain sequence that comprises a heavy chain variable region having CDRH1 , CDRH2 , and CDRH3 , wherein CDRH1 comprises the amino acid sequence of SEQ ID NO: 44 , CDRH2 comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 45 and SEQ ID NO: 97 , and CDRH3 comprises the amino acid sequence of SEQ ID NO: 46 , wherein the antibody or antigen binding fragment thereof binds a Siglec-15 protein comprising the amino acid sequence of SEQ ID NO: 2 or 4.2. The antigen binding fragment of claim 1 , selected from the group consisting of Fab claim 1 , F(ab′)2 claim 1 , Fab′ and Fv.3. The antibody or antigen binding fragment of claim 1 , wherein the antigen binding fragment is an scFv.4. The antibody or antigen binding fragment of claim 1 , wherein the antibody is a chimeric antibody.5. The antibody or antigen binding fragment of claim 1 , wherein the antibody or antigen binding fragment is humanized.6. The antibody or antigen binding fragment of claim 1 , wherein CDRH2 comprises the amino acid sequence of SEQ ID NO: 45.7. The antibody or antigen binding fragment of claim 1 , wherein CDRH2 comprises the amino acid sequence of SEQ ID NO: 97.8. A polynucleotide encoding the antibody of antigen binding fragment of .9. A vector ...

Antibody targeting osteoclast-related protein Siglec-15

To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.

Antibody targeting osteoclast-related protein siglec-15

To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.

Remedies for bone metabolic errors

A complex comprising OCIF and polysaccharide

Method for diagnosing bone dysbolism

Novel protein and methods for the production of the same

Methods for using the osteoclastogenesis inhibitory factor (OCIF) protein

A protein which inhibits osteoclast differentiation and/or maturation and a method of production of the protein. The protein is produced by human embryonic lung fibroblasts and has molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis, respectively. The protein can be isolated and purified from culture medium of the said fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity to the protein or a method for determination of the protein concentration using the antibodies.

Novel protein and methods for the production of the same

Proteins and methods for producing the proteins

A protein which inhibits osteoclast differentiation and/or maturation and a method for producing the protein. The protein is produced by human embryonic lung fibroblasts and has a molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis[[, respectively]]. The protein can be isolated and purified from the culture medium of fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity for the protein or a method for determining protein concentration using these antibodies.

Anti-Siglec-15 antibody

Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.

Method of diagnosing metabolic bone diseases

A method of diagnosing metabolic bone diseases, especially osteoporosis and arthrosis characterized by determining the concentration of osteoclastgenesis inhibitory factor (OCIF) in humor. Monoclonal antibodies recognizing equally both of monomer type and dimer type of OCIF. Monoclonal antibodies recognizing selectively dimer type of OCIF. And to provide an assay kit for determination of OCIF concentration comprising the aforementioned two antibodies recognizing different epitope of OCIF and having high affinity showing dissociation constant of less than 2×10−7 M with antigen. It is useful for a method of diagnosing metabolic bone diseases, especially osteoporosis and arthrosis or for an assay reagent for research thereof.

ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN SIGLEC-15

An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109. 1. An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption , or a functional fragment thereof comprising (a) a heavy chain comprising a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106 , a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107 , and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 80 , 55 , 65 , 35 or 45; and (b) a light chain comprising a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 83 or 73 , a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108 , and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 90 , 60 , 100 , 70 , 40 , 50 or 109.2. The isolated antibody or functional fragment thereof according to claim 1 , wherein the CDRH1 comprises a sequence having at least 80% sequence identity to one of SEQ ID NOS: 78 claim 1 , 53 claim 1 , 63 claim 1 , 33 or 43.3. The isolated antibody or functional fragment thereof according to claim 1 , wherein the CDRH2 ...

Bone-pathobolism treating agent

A novel bone-pathobolism treating agent is provided. A bone-pathobolism treating agent comprising at least one substance selected from the group consisting of osteoclastogenesis inhibitory factor (OCIF), its homologs, and its variants and a polysaccharide or its derivatives. As the polysaccharide or its derivatives, heparin, dextran sulfate and the like can be used. A bone-pathobolism treating agent is provided which has excellent therapeutic effect on bone-pathobolism such as osteoporosis, hypercalcemia, or chronic articular rheumatism and persistance of the activity. The agent is useful as a medicine.

Generating device

A generating device to supply electricity to a monitoring device of abnormal state of tire at a lower cost for a long time. The generating device includes a single pendulum 4, a hammer 6 supported at a point S′ on the circumference of a wheel 2, a spring 7 joining the single pendulum 4 and the hammer 6 by soft join, piezoceramics 8a and 8b converting distortion generated by the vibration adding force from the hammer 6 into a form of electricity, and cushion members 9a and 9b holding the positions of the piezoceramics 8a and 8b. A single pendulum 2 has vibrational frequency as same as or of integral multiplication of the rotational frequency of a tire 1.

ANTIBODIES THAT BIND TO OBM

Novel proteins and polypeptides binding to osteoclastogenesis inhibitory factor (OCIF) (OCIF-binding molecules, OBMs) and nucleic acids encoding these proteins and polypeptides are provided. Processes for producing these proteins, polypeptides, and nucleic acid molecules by genetic engineering are provided. Medicinal compounds are provided which comprise proteins and nucleic acids according to the invention, as well as proteins which bind to OBM, including anti-OBM antibodies. These compounds may be used for the treatment of bone disease.

Novel proteins and methods for producing the proteins

A protein which inhibits osteoclast differentiation and/or maturation and a method of production of the protein. The protein is produced by human embryonic lung fibroblasts and has molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis, respectively. The protein can be isolated and purified from culture medium of the said fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity to the protein or a method for determination of the protein concentration using the antibodies.

Complex comprising OCIF and polysaccharide

A complex comprising at least one substance selected from the group consisting of an osteoclastogenesis inhibitory factor, an analogue thereof and a variant thereof, which is bound to at least one substance selected from the group consisting of a polysaccharide and a polysaccharide derivative. The complex has a prolonged retention in the bloodstream after administration, making it useful in the treatment and prophylaxis of bone metabolic diseases.

Novel protein and method for producing the protein

A novel protein which binds to Osteoclastogenesis Inhibitory Factor (OCIF-binding molecule; OBM), a process for preparing the same, DNA encoding said protein, a protein having an amino acid sequence encoded by this DNA, a method for producing said protein by genetic engineering technique, and a pharmaceutical composition containing said protein. Screening methods for a substance for controlling expression of said protein using said protein and the DNA, a substance which inhibits or modulates the biological activity of said protein, or a receptor which transmits the action of said protein through binding to said protein, the substance obtained by the screening methods, and a pharmaceutical composition which contains this substance. An antibody for said protein, a process for preparing the same, a measuring method of said protein using the antibody, and a medicine comprising this antibody.

Bone-pathobolism treating agent

A novel bone-pathobolism treating agent is provided. A bone-pathobolism treating agent comprising at least one substance selected from the group consisting of osteoclastogenesis inhibitory factor (OCIF), its homologs, and its variants, and a polysaccharide or its derivatives. As the polysaccharide or its derivatives, heparin, dextran sulfate and the like can be used. A bone-pathobolism treating agent is provided which has excellent therapeutic effect on bone-pathobolism such as osteoporosis, hypercalcemia, or chronic articular rheumatism and persistance of the activity. The agent is useful as a medicine.

Novel proteins and methods for producing the proteins

A protein which inhibits osteoclast differentiation and/or maturation and a method for producing the protein. The protein is produced by human embryonic lung fibroblasts and has a molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis. The protein can be isolated and purified from the culture medium of fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity for the protein or a method for determining protein concentration using these antibodies.

Methods for identifying a substance which specifically binds to an osteoclastogenesis inhibitory factor-binding molecule and modulates the biological activity thereof

The present invention relates to a novel protein which binds to Osteoclastogenesis Inhibitory Factor (OCIF-binding molecule; OBM), a process for preparing the same, DNA encoding said protein, a protein having an amino acid sequence encoded by this DNA, a method for producing said protein by genetic engineering technique, and a pharmaceutical composition containing said protein. In addition, screening methods for a substance for controlling expression of said protein using said protein and the DNA, a substance which inhibits or protein through binding to said protein, the substance obtained by the screening methods, and a pharmaceutical composition which contains this substance are disclosed. An antibody for said protein, a process for preparing the same, a measuring method of said protein using the antibody, and a medicine comprising the antibody are also disclosed.

Antibody targeting osteoclast-related protein Siglec-15

To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.

Antibodies to OCIF-binding molecules

A novel protein which binds to Osteoclastogenesis Inhibitory Factor (OCIF-binding molecule; OBM), a process for preparing the same, DNA encoding said protein, a protein having an amino acid sequence encoded by this DNA, a method for producing said protein by genetic engineering technique, and a pharmaceutical composition containing said protein. Screening methods for a substance for controlling expression of said protein using said protein and the DNA, a substance which inhibits or modulates the biological activity of said protein, or a receptor which transmits the action of said protein through binding to said protein, the substance obtained by the screening methods, and a pharmaceutical composition which contains this substance. An antibody for said protein, a process for preparing the same, a measuring method of said protein using the antibody, and a medicine comprising this antibody.

Methods of administering anti-Siglec-15 antibody

Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.

ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15

To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.

Antibodies to OCIF-binding molecules

A novel protein which binds to Osteoclastogenesis Inhibitory Factor (OCIF-binding molecule; OBM), a process for preparing the same, DNA encoding said protein, a protein having an amino acid sequence encoded by this DNA, a method for producing said protein by genetic engineering technique, and a pharmaceutical composition containing said protein. Screening methods for a substance for controlling expression of said protein using said protein and the DNA, a substance which inhibits or modulates the biological activity of said protein, or a receptor which transmits the action of said protein through binding to said protein, the substance obtained by the screening methods, and a pharmaceutical composition which contains this substance. An antibody for said protein, a process for preparing the same, a measuring method of said protein using the antibody, and a medicine comprising this antibody.

Antibody targeting osteoclast-related protein Siglec-15

An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.

Antibody targeting osteoclast-related protein siglec-15

To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.

Novel Protein and method for producing the protein

A novel protein which binds to Osteoclastogenesis Inhibitory Factor (OCIF-binding molecule; OBM), a process for preparing the same, DNA encoding said protein, a protein having an amino acid sequence encoded by this DNA, a method for producing said protein by genetic engineering technique, and a pharmaceutical composition containing said protein. Screening methods for a substance for controlling expression of said protein using said protein and the DNA, a substance which inhibits or modulates the biological activity of said protein, or a receptor which transmits the action of said protein through binding to said protein, the substance obtained by the screening methods, and a pharmaceutical composition which contains this substance. An antibody for said protein, a process for preparing the same, a measuring method of said protein using the antibody, and a medicine comprising this antibody.

Method of diagnosing metabolic bone diseases

A method of diagnosing metabolic bone diseases, especially osteoporosis and arthrosis characterized by determining the concentration of osteoclastgenesis inhibitory factor (OCIF) in humor. Monoclonal antibodies recognizing equally both of monomer type and dimer type of OCIF. Monoclonal antibodies recognizing selectively dimer type of OCIF. And to provide an assay kit for determination of OCIF concentration comprising the aforementioned two antibodies recognizing different epitope of OCIF and having high affinity showing dissociation constant of less than 2x10^-7 M with antigen. It is useful for a method of diagnosing metabolic bone diseases, especially osteoporosis and arthrosis or for an assay reagent for research thereof.

Proteins and methods for producing the proteins

A protein which inhibits osteoclast differentiation and/or maturation and a method for producing the protein. The protein is produced by human embryonic lung fibroblasts and has a molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis. The protein can be isolated and purified from the culture medium of fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity for the protein or a method for determining protein concentration using these antibodies.

Novel proteins and methods for producing the proteins

A protein which inhibits osteoclast differentiation and/or maturation and a method of production of the protein. The protein is produced by human embryonic lung fibroblasts and has molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis, respectively. The protein can be isolated and purified from culture medium of the said fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity to the protein or a method for determination of the protein concentration using the antibodies.

Methods of reducing bone absorption comprising administering an antibody that binds OBM

Novel proteins and polypeptides binding to osteoclastogenesis inhibitory factor (OCIF) (OCIF-binding molecules, OBMs) and nucleic acids encoding these proteins and polypeptides are provided. Processes for producing these proteins, polypeptides, and nucleic acid molecules by genetic engineering are provided. Medicinal compounds are provided which comprise proteins and nucleic acids according to the invention, as well as proteins which bind to OBM, including anti-OBM antibodies. These compounds may be used for the treatment of bone disease.

Anti-Siglec-15 antibody

Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.

METHODS OF IDENTIFYING OBM MODULATORS

Novel proteins and polypeptides binding to osteoclastogenesis inhibitory factor (OCIF) (OCIF-binding molecules, OBMs) and nucleic acids encoding these proteins and polypeptides are provided. Processes for producing these proteins, polypeptides, and nucleic acid molecules by genetic engineering are provided. Medicinal compounds are provided which comprise proteins and nucleic acids according to the invention, as well as proteins which bind to OBM, including anti-OBM antibodies. These compounds may be used for the treatment of bone disease.

ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15

To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like. 1. An antibody or an antigen binding fragment thereof , which specifically recognizes any one of the following polypeptides (a)-(i) , or any combination thereof , and inhibits osteoclast formation and/or osteoclastic bone resorption:(a) the amino acid sequence of SEQ ID NO: 2;(b) amino acid residues 21 to 328 of the amino acid sequence of SEQ ID NO: 2;(c) amino acid residues 1 to 260 of the amino acid sequence of SEQ ID NO: 2;(d) amino acid residues 21 to 260 of the amino acid sequence of SEQ ID NO: 2;(e) the amino acid sequence of SEQ ID NO: 4;(f) amino acid residues 21 to 341 of the amino acid sequence of SEQ ID NO: 4;(g) amino acid residues 1 to 258 of the amino acid sequence of SEQ ID NO: 4;(h) amino acid residues 21 to 258 of the amino acid sequence of SEQ ID NO: 4; or(i) an amino acid sequence including substitution, deletion, or addition of one or more a min acid residue in the amino acid sequence described in (a) to (h) wherein the amino acid sequence has a biological activity comparable to that of the amino acid sequence described in (a) to (h).2. The antibody or antigen binding fragment of claim 1 , wherein the antibody is a monoclonal antibody.3. The antibody or antigen binding fragment of claim 1 , wherein the antibody is an IgG antibody.4. The antibody or antigen binding fragment of claim 1 , wherein the antibody or antigen binding fragment competes with an antibody ...

ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN SIGLEC-15

To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.

ANTI-Siglec-15 ANTIBODY

Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.

Antibody targeting osteoclast-related protein Siglec-15

To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.

Nucleic acid molecules encoding osteoclastogenesis inhibitory factor proteins

A protein which inhibits osteoclast differentiation and/or maturation and a method for producing the protein. The protein is produced by human embryonic lung fibroblasts and has a molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis. The protein can be isolated and purified from the culture medium of fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity for the protein or a method for determining protein concentration using these antibodies.

Complex comprising OCIF and polysaccharide

A complex comprising at least one substance selected from the group consisting of an osteoclastogenesis inhibitory factor, an analogue thereof and a variant thereof, which is bound to at least one substance selected from the group consisting of a polysaccharide and a polysaccharide derivative. The complex has a prolonged retention in the bloodstream after administration, making it useful in the treatment and prophylaxis of bone metabolic diseases.

Novel proteins and methods for producing the proteins

A protein which inhibits osteoclast differentiation and/or maturation and a method for producing the protein. The protein is produced by human embryonic lung fibroblasts and has a molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis. The protein can be isolated and purified from the culture medium of fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity for the protein or a method for determining protein concentration using these antibodies.

Antibodies to OCIF-binding molecules

A novel protein which binds to Osteoclastogenesis Inhibitory Factor (OCIF-binding molecule; OBM), a process for preparing the same, DNA encoding said protein, a protein having an amino acid sequence encoded by this DNA, a method for producing said protein by genetic engineering technique, and a pharmaceutical composition containing said protein. Screening methods for a substance for controlling expression of said protein using said protein and the DNA, a substance which inhibits or modulates the biological activity of said protein, or a receptor which transmits the action of said protein through binding to said protein, the substance obtained by the screening methods, and a pharmaceutical composition which contains this substance. An antibody for said protein, a process for preparing the same, a measuring method of said protein using the antibody, and a medicine comprising this antibody.

Antibodies to OCIF-binding molecules

A novel protein which binds to Osteoclastogenesis Inhibitory Factor (OCIF-binding molecule; OBM), a process for preparing the same, DNA encoding said protein, a protein having an amino acid sequence encoded by this DNA, a method for producing said protein by genetic engineering technique, and a pharmaceutical composition containing said protein. Screening methods for a substance for controlling expression of said protein using said protein and the DNA, a substance which inhibits or modulates the biological activity of said protein, or a receptor which transmits the action of said protein through binding to said protein, the substance obtained by the screening methods, and a pharmaceutical composition which contains this substance. An antibody for said protein, a process for preparing the same, a measuring method of said protein using the antibody, and a medicine comprising this antibody.

Novel proteins and methods for producing the proteins

A protein which inhibits osteoclast differentiation and/or maturation and a method for producing the protein. The protein is produced by human embryonic lung fibroblasts and has a molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis. The protein can be isolated and purified from the culture medium of fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity for the protein or a method for determining protein concentration using these antibodies.

Antibodies to OCIF-binding molecules

The present invention relates to a novel protein which binds to Osteoclastogenesis Inhibitory Factor (OCIF-binding molecule; OBM), a process for preparing the same, DNA encoding said protein, a protein having an amino acid sequence encoded by this DNA, a method for producing said protein by genetic engineering technique, and a pharmaceutical composition containing said protein. In addition, screening methods for a substance for controlling expression of said protein using said protein and the DNA, a substance which inhibits or modulates the biological activity of said protein, or a receptor which transmits the action of said protein through binding to said protein, the substance obtained by the screening methods, and a pharmaceutical composition which contains this substance are disclosed. An antibody for said protein, a process for preparing the same, a measuring method of said protein using the antibody, and a medicine comprising the antibody are also disclosed.

Novel proteins and methods for producing the proteins

A protein which inhibits osteoclast differentiation and/or maturation and a method of production of the protein. The protein is produced by human embryonic lung fibroblasts and has molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis, respectively. The protein can be isolated-and purified from culture medium of the said fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity to the protein or a method for determination of the protein concentration using the antibodies.

Novel proteins and methods for producing the proteins

A protein which inhibits osteoclast differentiation and/or maturation and a method of production of the protein. The protein is produced by human embryonic lung fibroblasts and has molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis, respectively. The protein can be isolated and purified from culture medium of the said fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity to the protein or a method for determination of the protein concentration using the antibodies.

Monoclonal antibodies that bind OCIF

A protein which inhibits osteoclast diffraction and/or maturation and a method for producing the protein. The protein is produced by human embryonic lung fibroblasts and has a molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions an SDS-polyacrylamide gel electrophoresis. The protein can be isolated and purified from the culture medium of fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity for the protein or a method for determining protein concentration using these antibodies.

Novel protein and processes for producing the same

A novel protein and a process of producing the protein is provided. The protein is a glycoprotein having activity of suppressing the differentiation and/or maturation of adipocyte, having a molecular weight of about 45 kD under non-reducing conditions and about 28 kD and/or 23 kD under reducing conditions, and exhibiting affinity to heparin. A process of producing the protein comprising culturing human fibroblasts and purifying the culture broth by chromatography using an ion exchange column, affinity column, and reverse phase column. A cDNA encoding the protein and a process of producing the protein using the cDNA are also provided. The protein of the present invention is useful as a pharmaceutical composition for preventing or treating obesity or as an antigen for establishing immunological diagnosis, etc., ...

Complex comprising OCIF and polysaccharide

A complex comprising at least one substance selected from the group consisting of an osteoclastogenesis inhibitory factor, an analogue thereof and a variant thereof, which is bound to at least one substance selected from the group consisting of a polysaccharide and a polysaccharide derivative. The complex has a prolonged retention in the bloodstream after administration, making it useful in the treatment and prophylaxis of bone metabolic diseases.

ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN SIGLEC-15

To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.

Method for diagnosing bone dysbolism

A method of diagnosing metabolic bone diseases, especially osteoporosis and arthrosis characterized by determining the concentration of osteoclastgenesis inhibitory factor (OCIF) in humor. Monoclonal antibodies recognizing equally both of monomer type and dimer type of OCIF. Monoclonal antibodies recognizing selectively dimer type of OCIF. And to provide an assay kit for determination of OCIF concentration comprising the aforementioned two antibodies recognizing different epitope of OCIF and having high affinity showing dissociation constant of less than 2×10 −7 M with antigen. It is useful for a method of diagnosing metabolic bone diseases, especially osteoporosis and arthrosis or for an assay reagent for research thereof.

PEDIATRIC OSTEOPOROSIS DRUG THAT DOES NOT CAUSE GROWTH DISORDER

An object of the present invention is to provide a pharmaceutical agent for the treatment and/or prophylaxis of pediatric osteoporosis without causing bone growth disorder in a subject to be medicated. A pharmaceutical composition for the treatment and/or prophylaxis of pediatric osteoporosis contains an antibody or a functional fragment thereof which binds to Siglec-15 and has activity of suppressing formation of osteoclasts and/or bone resorption by osteoclasts. 1. A method for the treatment of pediatric osteoporosis , the method comprising administering an antibody or a functional fragment thereof which binds to Siglec-15 and has activity of suppressing formation of osteoclasts and/or bone resorption by osteoclasts.2. The method according to claim 1 , wherein the antibody does not cause growth disorder claim 1 , abnormal bone structure and/or abnormal bone quality.3. The method according to claim 1 , wherein the pediatric osteoporosis is pediatric osteoporosis developed due to drug administration.4. The method according to claim 1 , wherein the pediatric osteoporosis is pediatric steroid-induced osteoporosis.5. The method according to claim 1 , wherein the antibody is a monoclonal antibody.6. The method according to claim 1 , wherein the antibody consists of a heavy chain containing CDRH1 consisting of the amino acid sequence set forth as SEQ ID NO: 12 in Sequence Listing claim 1 , CDRH2 consisting of the amino acid sequence set forth as SEQ ID NO: 13 in Sequence Listing and CDRH3 consisting of the amino acid sequence set forth as SEQ ID NO: 14 in Sequence Listing claim 1 , and a light chain containing CDRL1 consisting of the amino acid sequence set forth as SEQ ID NO: 15 in Sequence Listing claim 1 , CDRL2 consisting of the amino acid sequence set forth as SEQ ID NO: 16 in Sequence Listing and CDRL3 consisting of the amino acid sequence set forth as SEQ ID NO: 17 in Sequence Listing.7. The method according to claim 1 , wherein the antibody is a chimeric antibody ...

製版機のシートロール検出装置

(57)【要約】 【課題】 異なった種類の感光性シートロールを自動的 判別できる製版機のシートロール検出装置を得るにあ る。 【解決手段】 画像情報を露光する露光装置６，１０に 対して、感光性シートロールＳＲを切断して供給できる シートロール供給部２０及びマスター供給部４０を付設 する製版機において、前記感光性シートロールＳＲの裏 面を照明する光源及び同裏面からの反射光を入射される 受光素子からなるマスター種別センサＳ 0 を前記シート ロール供給部２０の取入部ガイド３２に位置し、同マス ター種別センサＳ 0 の受光部Ｓ 0a の受光量により感光性 シートロールＳＲの種類を判別する製版機のシートロー ル検出装置。

Anti-siglec-15 antibody

Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.

ANTI-Siglec-15 ANTIBODY.

La presente invención se refiere a un anticuerpo aislado o un fragmento funcional del anticuerpo, que se une a un polipéptido, caracterizado porque comprende los residuos de aminoácidos 39 a 165 de una secuencia de aminoácidos representada por SEQ ID NO: 2 e inhible la formación de osteoclastos y/o resorción osteoclástica de hueso, en donde l anticuerpo o fragmento funcional del mismo comprende; una secuencia de cadena pesada que contiene una región variable que tiene CDRH1, CDRH2 y CDRH3, y la CDRH1 comprende una secuencia de aminoácidos representada por SEQ ID NO: 44, la CDRH2 comprende cualquiera de las secuencia de aminoácidos representadas por SEQ ID NO: 45 y SEQ ID NO: 97 y la CDRH3 comprende una secuencia de aminoácidos representada por SEQ ID NO: 46; y una secuencia de cadena ligera contiene una región variable que tiene CDRL1, CDRL2 y CDRL3, y la CDRL1 comprende una secuencia de aminoácidos representada por SEQ ID NO: 47, la CDRL2 comprende una secuencia de aminoácidos representada por SEQ ID NO: 48, y la CDRL3 comprende una secuencia de aminoácidos representada por SEQ ID NO. 49, y en donde el anticuerpo no es el anticuerpo producido por hibridoma FERM BP-10999.

NEW PROTEIN AND METHOD FOR THE PRODUCTION THEREOF

Novel osteoclastogenesis inhibitory factor and methods for producing same

A protein which inhibits osteoclast differentiation and/or maturation and a method of production of the protein. The protein is produced by human embryonic lung fibroblasts and has molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis, respectively. The protein can be isolated and purified from culture medium of the said fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity to the protein or a method for determination of the protein concentration using the antibodies.

ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15

To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. [Means for Resolution] Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.

antibody or functional antibody fragment, pharmaceutical composition, use of an antibody or functional fragment thereof, polynucleotide, vector, and transformed host cell.

Antibody targeting osteoclast-related protein siglec-15

To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. [Means for Resolution] Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.

Complex consisting of osteoclastogenesis inhibiting factor and polysaccharide

A novel complex comprising at least one substance selected from the group consisting of osteoclastogenesis inhibitory factor (OCIF), analogues thereof and variants thereof, which is bound to at least one substance selected from the group consisting of polysaccharides and derivatives thereof shows prolonged retention in the bloodstream after administration making it useful in the treatment and prophylaxis of bone metabolic diseases.

A sustained-release preparation having osteoconductive activity

Modified tcf

Modified TCF in which amino-acid residue(s) of the wild-type TCF responsible for glycosylation is (are) substituted or deleted so that at least one N-linked oligosaccharide chain is removed. The modified TCF have longer biological half-lives without loss of its biological activities. The modified TCFs are therapeutically important as agents for liver diseases or as anti-cancer drugs.

New protein and process to produce the same

LA INVENCION SE REFIERE A UNA NUEVA PROTEINA QUE SE UNE AL FACTOR INHIBIDOR DE LA OSTEOCLASTOGENESIS (MOLECULA QUE SE UNE A OCIF; OBM), A UN PROCEDIMIENTO DE PREPARACION DE LA MISMA, AL ADN QUE CODIFICA PARA LA MISMA, A UNA PROTEINA QUE TIENE LA SECUENCIA AMINOACIDA CODIFICADA POR DICHO ADN, A UN PROCEDIMIENTO DE PRODUCCION DE DICHA PROTEINA MEDIANTE INGENIERIA GENETICA, Y A UNA COMPOSICION FARMACEUTICA QUE CONTIENE DICHA PROTEINA. SE PRESENTAN TAMBIEN PROCEDIMIENTOS DE SELECCION PARA UNA SUSTANCIA DESTINADA A CONTROLAR LA EXPRESION DE DICHA PROTEINA, UTILIZANDO DICHA PROTEINA Y EL ADN, UNA SUSTANCIA QUE INHIBE O MODULA LA ACTIVIDAD BIOLOGICA DE DICHA PROTEINA, O UN RECEPTOR QUE TRANSMITE LA ACCION DE DICHA PROTEINA MEDIANTE SU UNION A DICHA PROTEINA. ASIMISMO, SE PROPORCIONA LA SUSTANCIA OBTENIDA MEDIANTE DICHO PROCEDIMIENTO DE SELECCION Y UNA COMPOSICION FARMACEUTICA QUE CONTIENE DICHA SUSTANCIA. POR ULTIMO, LA INVENCION SUMINISTRA UN ANTICUERPO PARA DICHA PROTEINA, UN PROCEDIMIENTO DE PREPARACION DEL MISMO, UN PROCEDIMIENTO DE MEDICION DE DICHA PROTEINA UTILIZANDO DICHO ANTICUERPO Y UNA MEDICINA QUE COMPRENDE EL CITADO ANTICUERPO.

Remedies for bone metabolic errors

A novel bone-pathobolism treating agent is provided. A bone-pathobolism treating agent comprising at least one substance selected from the group consisting of osteoclastogenesis inhibitory factor (OCIF), its homologs, and its variants and a polysaccharide or its derivatives. As the polysaccharide or its derivatives, heparin, dextran sulfate and the like can be used. A bone-pathobolism treating agent is provided which has excellent therapeutic effect on bone-pathobolism such as osteoporosis, hypercalcemia, or chronic articular rheumatism and persistance of the activity. The agent is useful as a medicine.

Anti-siglec-15 antibody

Provided is an antibody which binds to a polypeptide comprising amino acid residues 39 to 165 of a specified Siglec-15 amino acid sequence and inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment of the antibody, wherein the antibody has specified sequences of the six CDRs.

ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15

ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15

Disclosed is an antibody, or a functional fragment of the antibody, which specifically recognizes one or more polypeptides comprising an amino acid sequence described in any one of the following (a) to (i) and inhibits osteoclast formation and/or osteoclastic bone resorption: (a) an amino acid sequence represented by SEQ ID NO: 2 in the Sequence Listing; (b) an amino acid sequence consisting of amino acid residues 21 to 328 of the amino acid sequence represented by SEQ ID NO: 2 in the Sequence Listing; (c) an amino acid sequence consisting of amino acid residues 1 to 260 of the amino acid sequence represented by SEQ ID NO: 2 in the Sequence Listing; (d) an amino acid sequence consisting of amino acid residues 21 to 260 of the amino acid sequence represented by SEQ ID NO: 2 in the Sequence Listing; (e) an amino acid sequence represented by SEQ ID NO: 4 in the Sequence Listing; (f) an amino acid sequence consisting of amino acid residues 21 to 341 of the amino acid sequence represented by SEQ ID NO: 4 in the Sequence Listing; (g) an amino acid sequence consisting of amino acid residues 1 to 258 of the amino acid sequence represented by SEQ ID NO: 4 in the Sequence Listing; (h) an amino acid sequence consisting of amino acid residues 21 to 258 of the amino acid sequence represented by SEQ ID NO: 4 in the Sequence Listing; and (i) an amino acid sequence including substitution, deletion or addition of one or several amino acid residues in the amino acid sequence described in (a) to (h). Also disclosed is the use of at least one of the antibodies or functional fragments of the antibodies for the manufacture of a medicament for treating and/or preventing abnormal bone metabolism.

Use of an antibody for the manufacture of a medicament for the treatment of bone metabolism abnormality.

Anti-Siglec-15 antibody

Pediatric osteoporosis drug that does not cause growth disorder

Method for diagnosing bone dysbolism

A method of diagnosing metabolic bone diseases, especially osteoporosis and arthrosis characterized by determining the concentration of osteoclastgenesis inhibitory factor (OCIF) in humor. Monoclonal antibodies recognizing equally both of monomer type and dimer type of OCIF. Monoclonal antibodies recognizing selectively dimer type of OCIF. And to provide an assay kit for determination of OCIF concentration comprising the aforementioned two antibodies recognizing different epitope of OCIF and having high affinity showing dissociation constant of less than 2×10 −7 M with antigen. It is useful for a method of diagnosing metabolic bone diseases, especially osteoporosis and arthrosis or for an assay reagent for research thereof.

COMPLEX INCLUDING OSTEOCLASTOGENESIS AND POLYSACCHARID INHIBITING FACTOR

SE REFIERE A UN COMPLEJO DE i)UN FACTOR INHIBIDOR DE OSTEOCLASTOGENESIS (OCIF) NATURAL O RECOMBINANTE MONOMERO O DIMERO CON PESO MOLECULAR DEL OCIF MONOMERICO DE 60000; OCIF DIMERICO DE 120000 MEDIDO BAJO CONDICIONES REDUCTORAS, QUE PUEDEN COMPRENDER LOS AMINOACIDOS -21 A +380 DE SEQ 1 (380 AMINOACIDOS), ANALOGOS DEL MISMO; QUE SE UNE A ii)POLISACARIDOS TAL COMO ACIDO HIALURONICO, ACIDO CONDROITINSULFURICO, ACIDO DERMATAN, HEPARITINA, ACIDO QUERATAN, CARRAGENINA, PECTINA, HEPARINA, DEXTRAN; EL COMPLEJO SE CARACTERIZA PORQUE LA RELACION ENTRE OCIF Y POLISACARIDOS ES 1:1 A 1:8; Y POR MEJORAR EL TIEMPO DE RETENCION DEBIDO A QUE LA FUERZA DE ADSORCION DEL COMPLEJO ES MENOR QUE LA FUERZA DE ADSORCION DEL OCIF LIBRE. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPLEJO EVITA QUE OCIF QUE ES UNA PROTEINA BASICA QUE TIENE UN PUNTO ISOELECTRICO ALREDEDOR DE 9 DESAPAREZCA RAPIDAMENTE DEL TORRENTE SANGUINEO Y PUEDA INHIBIR LA DIFERENCIACION DE CELULA PRECURSORA DE OSTEOCLASTO A OSTEOCLASTO EVITANDO LA RESORCION OSEA, POR LO QUE PUEDE SER UTIL PARA EL TRATAMIENTO DE ENFERMEDADES METABOLICAS OSEAS COMO OSTEOPOROSIS, OSTEOPENIA, ENFERMEDAD DE PAGET, OSTEOMIELITIS, FOCO INFECCIOSOS DEBIDO A PERDIDA DE HUESO, HIPERCALCEMIA

Method for diagnosis of metabolic bone diseases

A method of diagnosing metabolic bone diseases, especially osteoporosis and arthrosis characterized by determining the concentration of osteoclastgenesis inhibitory factor (OCIF) in humor. Monoclonal antibodies recognizing equally both of monomer type and diner type of OCIF. Monoclonal antibodies recognizing selectively diner type of OCIF. And to provide an assay kit for determination of OCIF concentration comprising the aforementioned two antibodies recognizing different epitope of OCIF and having high affinity showing dissociation constant of less than 2 x 10-7 M with antigen. It is useful for a method of diagnosing metabolic bone diseases, especially osteoporosis and arthrosis or for an assay reagent for research thereof.

ANTIBODY SPECIFIC TO OSTEOKLASTRELATERET PROTEIN Siglec-15

A protein which binds to osteoclastogenesis inhibitory factor (OCIF)

Housing bed apparatus

(57)【要約】 【課題】 製版機の加熱された機内空気の熱量を充分に 活用でき、セラミックヒータで加熱された内部空気が無 駄に排出されることのない製版機の定着装置を得るにあ る。 【解決手段】 マスターシートＸの通路の上下に配置さ れる上ハウジング９１Ａ及び下ハウジング９１Ｂを有し かつ前記マスターシートＸの幅方向に伸びた定着器ハウ ジング中で、マスターシートＸのトナー像を加熱定着さ せる定着装置を備えた製版機の定着装置において、機体 フレーム１の壁面１ｂに近接した位置から機内風を取り 入れるファンモータ９２、機内風を加熱するセラミック ヒータ９３、加熱された機内風を整流する整流版９４を 前記定着器ハウジングの幅方向両端部にそれぞれ配置 し、定着器ハウジング内部の加熱空気の一部を前記壁面 側に迂回させる通気孔９４，９５を前記定着器ハウジン グの端板９１Ｃに形成した製版機の定着装置。

Method for diagnosing metabolic bone disorders

Novel protein binding to osteoclastogenesis inhibitory factor and process for producing the same

A novel protein binding to osteoclastogenesis inhibitory factor (OCIF) (OCIF-binding molecule; OBM). A DNA encoding the above protein; a protein having the amino acid sequence encoded by this DNA; a process for producing this protein by the genetic engineering technique; and medicinal compositions containing this protein. A method for screening a substance regulating the expression of the above protein, a substance inhibiting or modifying the biological activity of the above protein, or a receptor binding to the above protein and thus mediating its function with the use of the above protein and the DNA thereof; substances thus obtained; and medicinal compositions containing the substances thus obtained. An antibody against the above protein; a method for assaying the above protein by using the antibody; and drugs containing the antibody.

Modified tcf

Facteur cytotoxique tumoral modifié, dans lequel le ou les résidu(s) amino-acide(s) du facteur cytotoxique tumoral de types naturels responsables de la glycosylation est ou sont substitués ou supprimés de manière à supprimer au moins une chaîne oligosaccharide de liaison N. Ce facteur cytotoxique tumoral ainsi modifié présente une demi-vie biologique plus longue sans perte des autres activités biologiques. Il présente une importance thérapeutique comme principe actif de médicaments contre les maladies du foie ou le cancer. Modified tumor cytotoxic factor, in which the amino acid residue (s) of tumor cytotoxic factor of natural types responsible for glycosylation is or are substituted or deleted so as to delete at least one N-link oligosaccharide chain This tumor cytotoxic factor thus modified has a longer biological half-life without loss of other biological activities. It is of therapeutic importance as an active ingredient in drugs against liver disease or cancer.

Human stanniocalcin and uses thereof to inhibit adipogenesis

A novel protein which is a glycoprotein having activities of suppressing the differentiation and/or maturation of adipocytes, having a molecular weight of about 45 kDa under nonreducing conditions and about 28 kDa and/or about 23 kDa under reducing conditions, and having an affinity for heparin. A process for producing the above protein which comprises culturing human fibroblasts and purifying the product from the liquid culture medium by ion exchange column, affinity column and reversed phase column chromatographs. A cDNA encoding the above protein and a process for producing the above protein by using this cDNA. This protein is useful in medicinal compositions aiming at preventing and/or treating obesity, as an antigen for establishing immunological diagnosis, etc.

Complex comprising ocif and polysaccharide

Egy új komplex, amely oszteoklasztogenezis inhibitoros faktort (OCIF-ot), annak analógjait vagy annak variánsait tartalmazza, és amelykötve van poliszacharidok és azok származékai közül legalább egyhez,meghosszabbodott retenciót mutat a véráramban beadás után, hasznossátéve azt csontanyagcsere-betegségek kezelésére és profilaxisára. Ó A novel complex comprising osteoclastogenesis inhibiting factor (OCIF), its analogues, or variants thereof, and bound to at least one of polysaccharides and their derivatives, exhibits prolonged retention in the blood stream after administration, and is useful for the treatment and prophylaxis of bone metabolic disorders. HE

PROTEIN OCIF AND METHODS FOR ITS PRODUCTION

Antibody targeting osteoclast-related protein Siglec-15

ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15

To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. [Means for Resolution] Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.

OCIF proteins, process for producing them, cDNA encoding them, OCIF variant, mutant and truncated OCIF cDNA, OCIF variant, mutant and truncated OCIF protein, genomic OCIF DNA, pharmaceutical composition comprising OCIF protein, variant, mutant and truncated OCIF protein, antibody thereto, use thereof for drug preparation, method for determining OCIF concentration, vector with inserted OCIF cDNA, host cell containing the vector and transformed E. coli strain .

Et protein som inhiberer osteoklastdifferensiering og/eller modning og en fremgangsmåte for fremstilling av proteinet. Proteinet fremstilles ved hjelp av humane, embryoniske lungefibroblaster og har en molekylvekt på ca. 60 kD og ca. 120 kD under ikke reduserende betingelser, ved SDS-polyakrylamidgelelektroforese. Proteinet kan isoleres og renses fra kulturmediet fra fibroblastene. Proteinet kan dessuten fremstilles ved hjelp av genteknikk. DNA for fremstilling av proteinet ved hjelp av genteknikk, antistoffer med spesifikk affinitet for proteinet eller en fremgangsmåte for bestemmelse av proteinkonsentrasjonen ved anvendelse av antistoffene, er også beskrevet. A protein that inhibits osteoclast differentiation and / or maturation and a method of producing the protein. The protein is produced by means of human embryonic lung fibroblasts and has a molecular weight of approx. 60 kD and approx. 120 kD under non-reducing conditions, by SDS-polyacrylamide gel electrophoresis. The protein can be isolated and purified from the culture medium from the fibroblasts. The protein can also be produced by genetic engineering. DNA for the production of the protein by genetic engineering, antibodies with specific affinity for the protein or a method for determining the protein concentration using the antibodies are also described.

ANTI-Siglec-15 ANTIBODY

Remedies for bone metabolic errors

Novel remedies for bone metabolic errors. These remedies comprise at least one member selected from the group consisting of osteoclastogenesis inhibitory factor (OCIF), analogs thereof and variants thereof and polysaccharides or derivatives thereof. As the polysaccharides or derivatives thereof, use may be made of heparin, dextran sulfate, etc. These remedies have excellent therapeutic effects on bone metabolic errors such as osteoporosis, hypercalcemia and rheumatoid arthritis and can sustain the activities over a long time, which makes them highly useful as drugs.

Methode zur diagnose von abnormalem knochenstoffwechsel

Plasmid das für die aminosäuresequenz von tcf-ii kodierende dns enthalt, transformierte zelle und produktion einer physiologisch aktiven substanz mit ihrer verwendung

Neues protein und verfahren zu dessen herstellung

Új fehérjék és eljárások a fehérjék előállítására

A találmány tárgya egyrészt egy fehérje, mely gátőlja az ősteőclastdifferenciációt és/vagy érést, másrészt eljárás a fehérjeelőállítására. A fehérjét hűmán embriőnális tüdő fibrőblast sejteksegítségével állítják elő. A fehérje mőlekűlasúlya SDS-pőliakrilamidgélelektrőfőrézissel vizsgálva nemredűkáló körülmények közöttmegközelítőleg 60kD és 120kD, redűkáló körülmények közöttmegközelítőleg 60kD. A fehérjét a fent említett fibrőblasttenyészmédiűmából el tűdják választani és tisztítani. Tővábbá előtűdják állítani a fehérjét géntechnőlógiai módszerekkel. A jelentalálmány őlyan cDNS-re is vőnatkőzik, amelynek a segítségévelgéntechnőlógiai módszerekkel állítják elő a fehérjét. A találmánytővábbá a fehérjéhez specifikűs affinitással rendelkező antitestekreis vőnatkőzik, illetve egy őlyan eljárásra, melynek sőrán azantitesteket használják fel a fehérje kőncentrációjánakmeghatárőzásáhőz. ŕ

'osteoclast-inhibitor faktor' (ocif) abgeleitete proteinen und methoden zu dessen gewinnung

Ocif protein und methoden zu dessen gewinnung

Novel Protein and Process for Producing The Same

インクジェットプリンタ

【課題】ノズルからのインクの吐出量の均一化を図ることができるインクジェットプリンタを提供すること。【解決手段】メディアに対して主走査方向に移動しつつ、メディアにインクを吐出するインクジェットヘッド１５と、インクジェットヘッド１５に複数設けられるノズル３１と、ノズル３１に対応して設けられると共に、ノズル３１からインクを吐出させる圧電素子４０と、圧電素子４０を駆動させる電圧を制御する制御装置２０と、を備え、制御装置２０は、圧電素子４０の駆動制御を行うことにより、メディアへのインクの吐出時におけるインクの吐出を行うノズル３１の数を調節すると共に、インクを吐出するノズル３１の数に応じて、圧電素子４０を駆動させる際の電圧を調節する。【選択図】図２

Belichtungssteuerung, fuer eine einaeugige spiegelreflexkamera

Belichtungssteuerung fuer eine einaeugige spiegelreflexkamera

ネットワークシステム及び仮想ネットワークインターフェースの自動作成及び設定方法

【課題】仮想ネットワークインタフェースの作成及び設定を容易に実行することができるネットワークシステム及び、仮想ネットワークインターフェースの自動作成及び設定方法を提供すること。 【解決手段】本発明にかかるネットワークシステムは、アプリケーションから指定されるアドレス情報と、仮想ネットワークのアドレス情報を互いに関連づけた具現化情報を格納する具現化情報格納手段１０５と、アプリケーションの要求に応じて、当該要求に含まれるアドレス情報に基づいて、対応する仮想ネットワーク情報を前記具現化情報格納手段より読み出して、設定する仮想ネットワークインタフェース具現化手段１０３とを備えている。 【選択図】図２

印刷システムおよび印刷装置

【課題】ユーザが傍らについていなくても、効率良く印刷を行える印刷システムを提供する。【解決手段】印刷システム１は、被印刷物を印刷するためのヘッドユニット、及び、被印刷物を載置するフラットベッドを有する印刷装置１０と、被印刷物を格納する第１のストッカ１１及び第２のストッカ１２と、被印刷物を載置したパレットを印刷装置１０に搬送する搬送ロボット１３と、搬送ロボット１３を印刷装置１０の位置まで移動可能なように案内するレール１４と、印刷装置１０および搬送ロボット１３を制御する制御装置とを備える。【選択図】図１